Is it safe or appropriate to use a vaginal cream containing sildenafil 1 % (Viagra), L‑arginine 10 %, and naltrexone 0.75 % applied to the clitoris for sexual dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Topical Sildenafil/Arginine/Naltrexone Cream for Clitoral Application

This compounded vaginal cream is not recommended based on current evidence, as the FDA has not approved sildenafil for use in women, and guideline-level evidence specifically advises against phosphodiesterase-5 inhibitors (PDE5i) for female sexual dysfunction due to lack of proven effectiveness. 1, 2

Why This Formulation Is Not Recommended

Sildenafil Component (1%)

The NCCN guidelines explicitly state: "Currently, the panel does not recommend the use of oral phosphodiesterase type 5 inhibitors (PDE5i) for female sexual dysfunction because of the lack of data regarding their effectiveness in women." 1 While sildenafil increases pelvic blood flow to the clitoris and vagina theoretically, randomized clinical trials showed contradictory results in women with sexual arousal disorder. 1

Critical FDA labeling information: Viagra (sildenafil) is "not for use in women or children. It is not known if VIAGRA is safe and effective in women or children under 18 years of age." 2 This is an off-label use without regulatory approval.

Recent Research Context

While a 2024 study of topical sildenafil cream 3.6% showed some promise in a subset of women with female sexual arousal disorder (particularly those without concomitant orgasmic dysfunction), this was an exploratory phase 2b trial 3. The overall intention-to-treat population showed no statistically significant differences between sildenafil and placebo for primary endpoints. Only in post-hoc subset analysis did certain groups show benefit. 3

Important safety concern: 21% of women in the sildenafil cream study experienced clitoral discomfort and "hypersensitivity," with 3 withdrawing from the study due to these effects. 4 This is a significant adverse effect rate for a topical genital application.

L-Arginine Component (10%)

There is insufficient evidence for L-arginine in female sexual dysfunction. The available research showing benefit is primarily in men with erectile dysfunction 5, which is not applicable to this clinical context.

Naltrexone Component (0.75%)

No evidence was provided regarding naltrexone's role in female sexual dysfunction, making this component entirely unsupported.

What Should Be Recommended Instead

The 2025 AUA/SUFU/AUGS guideline provides evidence-based alternatives for genitourinary syndrome of menopause and sexual dysfunction: 6

First-Line Approaches:

  • Local low-dose vaginal estrogen (cream, tablet, or ring) - Strong recommendation for improving vulvovaginal discomfort, dryness, and dyspareunia 6
  • Vaginal DHEA - Moderate recommendation for vulvovaginal dryness and dyspareunia 6
  • Water-, oil-, or silicone-based lubricants and moisturizers for vaginal dryness and sexual pain 1

Additional Evidence-Based Options:

  • Ospemifene (oral SERM) - Conditional recommendation for vulvovaginal dryness and dyspareunia 6
  • Pelvic floor muscle training - May improve sexual pain, arousal, lubrication, orgasm, and satisfaction 1
  • Psychotherapy/cognitive behavioral therapy - Particularly for women with psychosocial components 1

Clinical Pitfalls to Avoid

  1. Do not prescribe compounded formulations with unapproved ingredients when FDA-approved alternatives exist
  2. Do not assume male erectile dysfunction treatments translate to female sexual dysfunction - the physiology and evidence base differ significantly
  3. Assess for underlying causes before prescribing any treatment: cardiovascular disease, diabetes, medications (especially SSRIs, narcotics, hormone therapy), relationship issues, anxiety/depression 1
  4. Consider hormone status: If treatment-induced menopause is present, vaginal estrogen has the strongest evidence base 1, 6

Bottom Line

This triple-compound cream lacks guideline support and FDA approval. The sildenafil component is specifically not recommended by NCCN guidelines for female sexual dysfunction 1, and FDA labeling explicitly states it is not for use in women 2. Direct patients toward evidence-based treatments with proven safety profiles: local vaginal estrogen, vaginal DHEA, or ospemifene, combined with non-pharmacologic approaches like lubricants and pelvic floor therapy. 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.